Trial Profile

Evaluation of TAK-981 and TAK-981 Combinations Following Intratumoral CIVO Microdosing in Patients With Head and Neck Cancer

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 30 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Subasumstat (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Biomarker; Pharmacodynamics
Sponsors Presage Biosciences

Most Recent Events

28 Nov 2022 According to Presage Biosciences media release, spatial biology data was presented at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
28 Nov 2022 According to Presage Biosciences media release, preliminary findings from this study presented at American Association for Cancer Research (AACR) 2022 Annual Meeting
27 Jul 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com